-
1 Comment
PeptiDream Inc is currently in a long term downtrend where the price is trading 5.9% below its 200 day moving average.
From a valuation standpoint, the stock is 21.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 55.7.
PeptiDream Inc's total revenue rose by 1412.4% to $8B since the same quarter in the previous year.
Its net income has increased by 1634.3% to $4B since the same quarter in the previous year.
Finally, its free cash flow fell by 631.8% to $-323M since the same quarter in the previous year.
Based on the above factors, PeptiDream Inc gets an overall score of 3/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3836750004 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.3 |
|---|---|
| PE Ratio | 16.8 |
| Market Cap | 252B |
| Target Price | 3542.8572 |
| Dividend Yield | None |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. It also involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4587.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
